GBS CIPDAwareness Month

May 2025

Support. Advocacy. Education.

*The Freedom™ Infusion System is not intended to be used for treatment of GBS and has not been cleared by the FDA for this use. Refer to the Freedom™ Infusion System IFU for specific indications for use and compatible immunoglobulins.

KORU is proud to support our CIDP patients and raise awareness during GBS CIDP Awareness Month. The Freedom™ Infusion System is FDA-cleared for the subcutaneous administration of immunoglobulins, including Hizentra®^1,2, which is approved for the treatment of CIDP.³

Empowering people with CIDP

At KORU, we care about giving people with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) the freedom to enjoy life. CIDP affects 60,000 people in the US⁴, and their long-term outlook depends, among other things, on how the body responds to treatment.⁵ When treated appropriately, improvement can be expected in 50-80% of patients.⁵

Intravenous immunoglobulin (IVIg) infusions are an effective first-line treatment, but they often cause systemic side effects beyond just headaches, such as flu-like symptoms, nausea, and fatigue, which can lead to prolonged infusion times.⁶

Additionally, IVIg most often requires a healthcare provider to administer the drugs⁷, adding logistical challenges for many patients.⁷ By comparison, subcutaneous immunoglobulin (SCIg) infusions cause fewer systemic side effects⁸ and can be self-administered after proper training by a healthcare provider, offering CIDP patients greater independence.

Resources for patients and caregivers

KORU is proud to support people living with CIDP and their caregivers. Here are a few organizations that serve this community.

GBS | CIDP Foundation International

The GBS | CIDP Foundation International is a global nonprofit organization supporting individuals and their families affected by Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) and related conditions through a commitment to support, education, research and advocacy.
https://www.gbs-cidp.org/cidp/

KORU is a product sponsor of GBS | CIDP Foundation International.

IDF Resource Center

The Immune Deficiency Foundation’s online Resource Center has an abundance of materials and tools to help patients and family members of those with Primary Immunodeficiencies stay informed.
www.primaryimmune.org/resource-center

IG Living

Join the immune globulin community with access to IG Living magazine, advocacy groups, expert opinions, and patients with rare diseases.
www.igliving.com

National Organization for Rare Disorders

The National Organization for Rare Disorders (NORD)’s mission is to improve the health and well-being of people with rare diseases by driving advances in care, research and policy.
https://rarediseases.org/

Koru’s Patient Support Program is dedicated to supporting your success with at-home subcutaneous infusion therapy.
Download the Freedom Journey flyer

Additional Scientific Studies

Read these important studies deepening our understanding of CIDP and Ig infusion therapy.

Katzberg H, Lewis RA, Harbo T, Allen JA, Bullock M, Grosse-Kreul D, Smith JB, Bril V. Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy – Neurologist, Nursing and Patient Perspectives. European Neurological Review. 2019; 14(1): 44. doi:10.17925/ENR.2019.14.1.44.
Goyal NA, Karam C, Sheikh KA, Dimachkie MM. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64(3):243-254. doi:10.1002/mus.27356

Meet the Koru team at meetings and conferences for the CIDP community

IDF Teen & Tween Escape

July 18 – 20, 2025

Cincinnati, OH

GBS CIDP Symposium

September 11 – 13, 2025

Denver, CO

IDF Innovation Summit

October 8-9, 2025

Bethesda, MD

References

U.S. Food and Drug Administration. (2021, December 15). 510(k) Summary: FREEDOM™ Integrated Syringe Infusion System (K200176). https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200176.pdf
U.S. Food and Drug Administration. (2022, April 29). 510(k) summary: FreedomEdge® Syringe Infusion System (K214045). https://www.accessdata.fda.gov/cdrh_docs/pdf21/K214045.pdf
U.S. Food and Drug Administration. (2018, March 15). Approval letter for Hizentra (STN: BL 125350/641). https://www.fda.gov/media/111603/download
EL PFDD Meeting on CIDP. Meeting report, 2022. https://www.gbs-cidp.org/wp-content/uploads/2022/08/GBSCIDP-Voice-of-the-Patient-Report_Final.pdf . Published 2022. Accessed December 4, 2024.
Viala K, Mahieu E, Maisonobe T, et al. Chronic inflammatory demyelinating polyneuropathy:clinical characteristics and prognostic factors of long-term outcome. J Peripher Nerv Syst. 2010;15(3):220-229. doi:10.1111/j.1529-8027.2010.00283.x.
Younger ME, Aro L, Blouin W, et al. Nursing guidelines for administration of immunoglobulin replacement therapy. J Infus Nurs. 2013;36(1):58-68. doi:10.1097/NAN.0b013e3182798af8
Kirmse J. The nurse’s role in administration of intravenous immunoglobulin therapy. Home Healthc Nurse. 2009;27(2):104-113. doi:10.1097/01.NHH.0000346313.64380.da
Allmendinger A, Fischer S. Tissue Resistance during Large-Volume Injections in Subcutaneous Tissue of Minipigs [published correction appears in Pharm Res. 2020 Nov 30;37(12):251. doi: 10.1007/s11095-020-02970-1.]. Pharm Res. 2020;37(10):184. Published 2020 Sep 4. doi:10.1007/s11095-020-02906-9